Topic

Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

Democrats failed to gain sufficient support this week to advance long-debated legislation to permit Medicare drug price negotiations. 

Pharma Blocks Democrats’ Drug Pricing Plan

Legislative proposals for curbing outlays on prescription drugs have moved to center stage, as Congress looks hard for ways to pay for costly initiatives to repair the nation’s infrastructure, offset global warming and expand health care programs.

Will Price Controls Limit Drug Development? The Debate Heats Up

The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden.

Biden Highlights Drug Pricing Reforms to Advance Legislative Agenda

A broad White House proposal to advance competition in major U.S. industries features several measures intended to make medicines more affordable for patients. 

Drug Prices Targeted in Biden Competition Initiative

How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?

How a “Push and Pull” Approach Can Maximize Innovation Value through HTAs

David Bower is a Global Value & Access Lead for DUPIXENT in Dermatology indications at Sanofi Genzyme. Agata Wiśniowska is a senior consultant in Life Sciences at Guidehouse.

David Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments. 

Evolving a Market Access Strategy to Improve Patient Access

The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.

SPBMs: Impact on Accessibility & Affordability of Gene Therapies for Rare and Orphan Diseases

With Sen. Bernie Sanders leading the charge on Capitol Hill, the campaign to limit U.S. outlays for prescription drugs has accelerated.

Drug Pricing Moves to Top of Legislative Agenda

Leela Barham is a freelance health economist and policy expert. She has published in peer-reviewed journals and presented at national and international conferences. She has provided advice to the Department of Health and Social Care on policy on pricing of branded medicines to inform the negotiation of a successor to the UK’s Pharmaceutical Price Regulation Scheme (PPRS), the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), as well as worked with patient groups, the NHS, pharmaceutical companies and many others internationally on the economics of healthcare and pharmaceuticals. Contact Leela on leels@btinternet.com

We all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at  similar mistakes made in the past and what can be done about them.

Minimizing the Risk of Mistakes in HTA

Christian Schuler is Senior Partner in the Life Sciences division of Simon-Kucher & Partners

Benedikt Porten is Consultant in the Life Sciences division of Simon-Kucher & Partners.

How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.